| Literature DB >> 32213521 |
Niky Ghorbani1,2, Vivek Muthurangu3, Abbas Khushnood3, Leonid Goubergrits1,2, Sarah Nordmeyer1,2, Joao Filipe Fernandes1, Chong-Bin Lee1,4, Kilian Runte1, Sophie Roth1, Stephan Schubert2,5, Sebastian Kelle4,5, Felix Berger2,5, Titus Kuehne1,2,5, Marcus Kelm6,2,7.
Abstract
OBJECTIVE: We aimed to investigate the combined effects of arterial hypertension, bicuspid aortic valve disease (BAVD) and age on the distensibility of the ascending and descending aortas in patients with aortic coarctation.Entities:
Keywords: congenital heart disease; hypertension; paediatric cardiology; valvular heart disease
Mesh:
Year: 2020 PMID: 32213521 PMCID: PMC7170596 DOI: 10.1136/bmjopen-2019-034853
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Patient characteristics; median and lower and upper quantiles (Q1;Q3) and n (%)
| Total study group | Non-HTN group | HTN group | P value | |
| Characteristics | ||||
| Age (years) | 22 (15;31) | 22 (16;30) | 23 (15;31) | 0.760 |
| Male (n, %) | 80 (66) | 22 (65) | 58 (67) | 0.838 |
| Weight (kg) | 66.2 (51;78) | 59.25 (50.2;74) | 68 (51;80) | 0.183 |
| Height (cm) | 169 (153;177.5) | 167 (152.6;178) | 170 (153;177.5) | 0.674 |
| BMI (kg/m²) | 22.3 (19.36;25.16) | 21.24 (19.36;23.72) | 22.64 (19.1;25.3) | 0.324 |
| BSA (m²) | 1.74 (1.5;1.95) | 1.66 (1.47;1.93) | 1.8 (1.47;1.97) | 0.190 |
| Bicuspid aortic valve (n, %) | 52/121 (43) | 15/34 (44) | 37/87 (43) | 0.874 |
| Previous episodes of HTN and/or exercise HTN (n, %) | 98/121 (81) | 11/34 (32) | 87/87 (100) | 0.002 |
| Systolic BP (mm Hg) | 136 (122;148) | 116 (110;122) | 142 (134;152) | <0.001 |
| Diastolic BP (mm Hg) | 69 (62;77) | 66.5 (58;75) | 72 (63;80) | 0.006 |
| Echocardiographic pressure drop across stenosis (mm Hg) | 25 (13;41) | 25 (13;35) | 25 (14;45) | 0.289 |
| Patients with echocardiographic pressure drop above 20 mm Hg (n, %) | 81 (67) | 23 (68) | 58 (67) | 0.918 |
| Previous treatment | ||||
| Balloon angioplasty (n, %) | 45/121 (37) | 9/34 (26) | 36/87 (41) | 0.129 |
| Stenting (n, %) | 23/121 (19) | 4/34 (12) | 19/87 (22) | 0.206 |
| Surgical reconstruction (n, %) | 73/121 (60) | 23/34 (68) | 50/87 (57) | 0.306 |
| Antihypertensive medication (n, %) | 37/121 (31) | 11/34 (32) | 26/87 (30) | 0.791 |
| Type of medication | ||||
| Beta blockers (n, %) | 23/121 (19) | 7/34 (21) | 16/87 (18) | 0.783 |
| ACE inhibitors (n, %) | 22/121 (18) | 7/34 (21) | 15/87 (17) | 0.669 |
| Calcium channel blockers (n, %) | 11/121 (9) | 1/34 (3) | 10/87 (11) | 0.143 |
| Angiotensin receptor blockers (n, %) | 4/121 (3) | 1/34 (3) | 3/87 (3) | 0.889 |
| Diuretics (n, %) | 7/121 (6) | 3/34 (9) | 4/87 (5) | 0.373 |
| Diameter of the aorta | ||||
| Ascending aorta, minimum (mm) | 25 (19.9;30) | 26.05 (19.2;30) | 24.2 (20;30.3) | 0.802 |
| Ascending aorta, maximum (mm) | 29.09 (24;33.1) | 29.45 (24;32.7) | 28.4 (23.8;33.8) | 0.762 |
| Descending aorta, minimum (mm) | 17.9 (14.7;20.9) | 16.84 (13.8;20.3) | 17.9 (15;21) | 0.378 |
| Descending aorta, maximum (mm) | 20 (16.2;23.3) | 19.25 (15.8;23) | 20.1 (16.2;23.4) | 0.500 |
Pressure drop across the stenosis: maximal pressure in mm Hg across the coarctated segment measured by echocardiography; ascending and descending aortas (minimum) describing end-diastolic cross-sectional diameter; ascending and descending aortas (maximum) describing end-systolic cross-sectional diameter.
Continuous data are expressed as median and IQR (Q1;Q3), p values are from Wilcoxon-Mann-Whitney test. Categorical data are presented as frequencies and percentage (%), p values are from Pearson’s χ2 test.
BMI, body mass index; BP, blood pressure; BSA, body surface area; HTN, hypertension.
Figure 1Locations of cross-sectional diameter measurements of the ascending and descending aortas, measured during the end-systolic and end-diastolic heart phase
Figure 2Aortic distensibility of the ascending aorta (left) and descending aorta (right) in patients with or without accompanying HTN or BAVD, plotted against age. It includes the effects of (A) HTN on the ascending aorta, (B) HTN on the descending aorta, (C) BAVD on the ascending aorta and (D) BAVD on the descending aorta; BAVD, bicuspid aortic valve disease; HTN, hypertension.
Figure 3Estimated effects of antihypertensive medication on the distensibility of the descending aorta, compared with normotensive patients without medication (reference).
Figure 4Marginal effects and 95% CIs for impaired aortic distensibility (below the fifth percentile) of the ascending and descending aortas, in patients with or without hypertension (HTN) or bicuspid aortic valve disease (BAVD), plotted against age (*p<0.05; **p<0.01).